nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-83D6B372·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Physiology·Basis: Full text·Type: Diagnostic accuracy study

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP.

Kac et al.Kac, Cousins, Szadziewska et al.·2026·Acta neuropathologica·10.1007/s00401-026-03042-1 ↗

Primary claim

CSF p-tau181 and p-tau212, as well as p-tau181/tau368 and p-tau212/tau368, were higher in FTLD-tau compared with non-tau groups, and the diagnostic accuracy to discriminate FTLD-tau from FTLD-TDP improved.

Tentative · small retrospective subgroups, post hoc PSP exclusion, and inconsistent AUC reporting limit the claimed incremental accuracy
In brief

Autopsy-anchored CSF data identify promising FTLD-tau markers, but post hoc PSP exclusion and inconsistent AUC reporting make tau368’s incremental value provisional.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Across tauopathies-Alzheimer's disease (AD), frontotemporal lobar degeneration due to tau (FTLD-tau)-we compared cerebrospinal fluid (CSF) biomarkers of phosphorylated-tau (p-tau) p-tau181, p-tau212, tau368, total tau (t-tau), and the tau368/t-tau ratio, and tested differentiation from non-tau (FTLD-TDP, neuronal α-synuclein disease (αSyn), and controls). In AD, CSF p-tau181 and p-tau212 were significantly higher than in all other groups, including FTLD-tau, while tau368/t-tau was significantly lower. With the aim to combine tau phosphorylation biomarkers (p-tau181 and p-tau212) with biomarkers for severity of tau pathology (tau368), we made ratios between these biomarkers and examined their diagnostic accuracy in FTLD after excluding high/intermediate AD neuropathologic change (ADNC). CSF p-tau181 and p-tau212, as well as p-tau181/tau368 and p-tau212/tau368, were higher in FTLD-tau compared with non-tau groups, and the diagnostic accuracy to discriminate FTLD-tau from FTLD-TDP improved. Levels of the ratios were increased in behavioral and primary progressive aphasia variants of tauopathies when compared to FTLD-TDP. Furthermore, the biomarkers showed significant correlation with both FTLD-tau and AD tau burden at autopsy across brain regions. These results suggest unique patterns of increased relative levels of p-tau epitopes in CSF among ADNC and FTLD-tau could improve the diagnosis of tauopathies and inform inclusion criteria in clinical trial design.

Key Claims

Primary finding · Tentative

CSF p-tau181 and p-tau212, as well as p-tau181/tau368 and p-tau212/tau368, were higher in FTLD-tau compared with non-tau groups, and the diagnostic accuracy to discriminate FTLD-tau from FTLD-TDP improved.

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

small retrospective subgroups, post hoc PSP exclusion, and inconsistent AUC reporting limit the claimed incremental accuracy

Abstract; Results, FTLD ROC analysis
Quote verified
Secondary · Well-supported

In AD, CSF p-tau181 and p-tau212 were significantly higher than in all other groups, including FTLD-tau, while tau368/t-tau was significantly lower.

autopsy-defined AD comparisons and reported group medians consistently support the stated biomarker pattern

Abstract; Results, AD biomarker comparisons; Table 1
Quote verified
Secondary · Tentative

Levels of the ratios were increased in behavioral and primary progressive aphasia variants of tauopathies when compared to FTLD-TDP.

very small bvFTD groups and supplementary PPA analyses limit clinical-subtype inference

Abstract; Results, clinical variants; Fig. 5
Quote verified
Secondary · Tentative

the biomarkers showed significant correlation with both FTLD-tau and AD tau burden at autopsy across brain regions.

small exploratory correlations and incomplete within-FTLD significance limit the breadth of the statement

Abstract; Results, brain tau correlation sections
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Autopsy reference for central comparison

FTLD-tau and FTLD-TDP are defined neuropathologically, providing a strong reference standard for the headline disease comparison.

↳ Methods, Penn biomarker cohort participants

#contribution

Addresses an unmet biomarker need

The study targets the absence of reliable fluid biomarkers for FTLD-tau and connects the proposed markers to clinical-trial selection and differentiation of overlapping syndromes.

↳ Introduction, paragraph 1; Conclusions

#methodological rigour

Multiple safeguards in quantitative analysis

The analysis reports assay precision, FDR correction, bootstrap confidence intervals, and blinded case-level image quantification.

↳ Methods, Biomarker measurements; Microscopy; Statistical analyses

Limitations

#reporting

Central AUC reporting does not reconcile

The Results and Discussion report materially different AUCs for FTLD-tau versus FTLD-TDP, changing the apparent size of tau368’s incremental benefit.

↳ Results, FTLD ROC analysis; Discussion, FTLD diagnostic-performance paragraph

#methodological rigour

PSP exclusion is outcome informed

Four PSP cases were removed from the main ADNC-negative analysis after being identified as tau368-ratio outliers, while analyses retaining them appear only in supplementary material.

↳ Results, “CSF p-tau/tau368 ratios improve the diagnostic accuracy…”, paragraph 1

#positioning

Clinical claims exceed validation stage

The Conclusions predict fewer false results and improved diagnosis despite a small, single-biobank proof-of-concept cohort with no external validation.

↳ Discussion, limitations paragraph; Conclusions

Does this match your read? Add your assessment ↓

Nabu Commentary

The autopsy-defined FTLD comparison and rare paired CSF–pathology material support a meaningful early contribution. Methodological credit is tempered by the post hoc removal of PSP cases based on tau368-ratio behaviour, small FTLD subgroups, and lack of external validation. The principal reporting problem is that the Results and Discussion provide different AUCs for the same central comparisons, while the manuscript also calls a p=0.057 correlation significant and invokes mediation without a mediation analysis. The limitations section appropriately describes the work as initial validation, but the Conclusions make stronger claims about improved diagnosis and reduced false results.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.9±0.2

Contribution
3.2

The study tests p-tau/tau368 ratios against autopsy-defined FTLD pathology in a setting with no established fluid biomarker, providing a genuine but preliminary advance. Incremental value is clearest for p-tau181 and is limited by small subgroups and inconsistent performance reporting.

Introduction; Results, FTLD ROC analysis; Discussion, FTLD diagnostic-performance paragraph

there are no robust and reliable fluid biomarkers specific to FTLD-tau

Methodological Rigour
2.6

Autopsy reference diagnoses, assay precision, bootstrap AUC intervals, multiplicity correction, and blinded image quantification support the design. Methodological Rigour is constrained by the pathology-enriched spectrum, post hoc PSP exclusion, internally selected Youden cutpoints, unreported assay/pathology blinding, and unreconciled central analysis counts.

Methods, Penn biomarker cohort and Statistical analyses; Results, FTLD diagnostic-performance section

Analyses revealed that FTLD-tau PSP cases were outliers for tau368 ratio levels

Reporting
2.7

The question-to-analysis sequence is followable, but central AUCs differ between the Results and Discussion and sensitivity improvement is claimed without corresponding sensitivity estimates. The mediation and significant-correlation wording also exceeds the reported analysis.

Results, FTLD ROC analysis and “Tau368 mediates…”; Discussion, FTLD diagnostic-performance paragraph

CSF tau368 was negatively correlated with tau burden, although this did not reach significance

Positioning
3.2

The paper engages prior p-tau, MTBR-tau, PSP, and FTLD biomarker findings and explicitly acknowledges limited generalizability and the need for replication. Positioning remains below the stronger band because the Conclusions make clinical-improvement claims stronger than the proof-of-concept evidence supports.

Discussion, PSP discussion and limitations paragraph; Conclusions

replication and extension will be required before these assays can be applied for widespread clinical use

Reliability

Caveats4 of 4 checks


Results checkNoted
  • the biomarkers showed significant correlation with both FTLD-tau and AD tau burden at autopsy across brain regions: "The correlation was significantly negative, possibly reflecting accumulation of this fragment in the brain and proving the association between tau368 and tangle pathology." (Discussion, paragraph beginning “Having in mind the complex physiology”) vs "CSF tau368 was negatively correlated with tau burden, although this did not reach significance (r = − 0.44, 95% CI − 0.75–0.01, p = 0.057)" (Results, Tau368 mediates the correlation of p-tau biomarkers in the FTLD-tau group). The reported tau368 correlation has p = 0.057, above the stated 0.05 threshold, so the Discussion's assertion of statistical significance contradicts the Results. → Not supported by the paper's own data
  • CSF p-tau181 and p-tau212, as well as p-tau181/tau368 and p-tau212/tau368, were higher in FTLD-tau compared with non-tau groups, and the diagnostic accuracy to discriminate FTLD-tau from FTLD-TDP improved: "Thus, analyses in ADNC-negative subcohort excluded four PSP cases (n = 102)." (Results, CSF p-tau/tau368 ratios improve the diagnostic accuracy) vs "The figure shows levels of tau biomarkers in clinically healthy individuals without cognitive impairment (normal; n = 41), frontotemporal lobar degeneration type tau (FTLD-Tau; n = 21), frontotemporal lobar degeneration type TDP (FTLD-TDP; n = 21), and neuronal α-synuclein diseases (αSyn; n = 12)." (Figure 3 caption). Figure 3's group counts sum to 41 + 21 + 21 + 12 = 95, seven fewer than the stated post-exclusion cohort of 102, without an explanation identifying the correct analytic denominator. → Effect on result unclear
  • CSF p-tau181 and p-tau212, as well as p-tau181/tau368 and p-tau212/tau368, were higher in FTLD-tau compared with non-tau groups, and the diagnostic accuracy to discriminate FTLD-tau from FTLD-TDP improved: "p-tau181 (n = 130; 33 AD, 20 FTLD-tau, 17 FTLD-TDP, 18 αSyn, 42 Control)" (Methods, Biomarker measurements) vs "clinically healthy individuals without cognitive impairment (normal; n = 41)" (Figure 2 caption; corroborates Table 1 Normal group count). The Methods report p-tau181 measurements for 42 controls, one more than the 41 controls reported for the cohort, and the supplied text does not establish which count is correct. → Effect on result unclear
Reporting and transparencyNoted

AUC reporting does not consistently label the PSP inclusion basis, logistic-model effects are called hazard rates rather than odds ratios, and the correlation-method descriptions differ between Methods and Figure 4.

Ethics approval: declared

Reference IntegrityClean

126 references in manuscript 126 of 126 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceMethodological
Route to useNamed
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The authors describe this as a proof-of-concept study in a single rare autopsy cohort with small sample sizes, requiring future replication in larger cohorts before clinical use.

From the paper
“Accurate diagnosis will support recruitment for clinical trials and will allow patients to receive appropriate therapy.”

The paper names who would act on the findings (clinical trial recruiters and patients receiving therapy) and the purpose (diagnosis and differentiation of FTLD spectrum disorders).

Pathway

Neurologists and clinical trial teams would use CSF p-tau/tau368 ratio assays to distinguish FTLD-tau from FTLD-TDP, improving diagnosis and trial enrollment.

Barrier

The findings need replication in larger, more diverse cohorts, including sporadic cases and plasma-based testing, before the assays can be applied for widespread clinical use.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's disease

    2026 · Neurology and psychiatry

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. Divergent toxicity mechanisms of amyloid-beta aggregates arising from a single aggregation reaction

    2026 · Basic medicine

    Primary claim

    aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity

    Tentative
    Evidence Score
    2.8±0.2
    Reliability
    Caveats
  3. A timeline of tau-mediated synaptotoxicity

    2026 · Basic medicine

    Primary claim

    even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.

    Tentative
    Evidence Score
    3.2±0.2
    Reliability
    No concerns

How the rubric works →